Nuclera Secures $75 Million for Protein Technology Advancement
On October 16, 2024, Nuclera, a prominent biotechnology firm based in Cambridge, UK, announced the successful completion of a Series C financing round, securing an impressive USD $75 million (approximately £57 million). This funding round was spearheaded by Elevage Medical Technologies, which was supported by Patient Square Capital. Additional investment came from notable entities including British Patient Capital, Cambridge Innovation Capital, Jonathan Milner, and several others. The team at Taylor Wessing provided legal advice for this transaction, which is expected to significantly enhance the commercialization of Nuclera’s eProtein Discovery™ platform, particularly aiming to optimize protein expression and purification workflows in laboratories across the globe, especially within the US and Europe.
Nuclera's innovative eProtein Discovery system has been carefully engineered to streamline the often complex and time-consuming processes involved in protein expression and purification.
By automating construct screening, this benchtop protein system is capable of rapidly producing milligram quantities of high-quality proteins in less than 48 hours—a timeline that stands in stark contrast to the traditional methods that can take months or even years. This efficiency is achieved through the integration of cutting-edge technologies including digital microfluidics, protein quality assays, and cell-free protein synthesis, which collectively revolutionize how researchers access and utilize proteins within their laboratories. Notably, the eProtein Discovery system has already been adopted by various contract research organizations (CROs), biotech firms, biopharma companies, and esteemed academic institutions like University College London and the University of Cambridge.
As the CEO and co-founder of Nuclera, Dr. Michael Chen expressed his enthusiasm about the recent investment, emphasizing its potential to significantly enhance the efficiency of protein production for drug discovery processes. He stated, "This significant investment demonstrates continued confidence in our team, our eProtein Discovery system, and our potential to revolutionize the way proteins are made." Additionally, Dr. Michael Wasserman, COO of Elevage Medical Technologies, highlighted the increasing demand for Nuclera's innovative solutions, particularly as advancements in AI and structural biology propel the need for rapid access to custom proteins. With the backing of influential figures such as Dr. Jonathan Milner, the Chairman of the Nuclera Board of Directors and a renowned entrepreneur in the biotech space, Nuclera is positioning itself as a key player in transforming laboratory workflows and timelines associated with drug discovery.
They've invested in Nuclera
Get to know these Healthtech investors
| # | Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|---|
1 |  Elevage Medical Technologies | investment(s) investment(s) | more info | |||
2 |  Patient Square Capital | 1 investment(s) investment(s) | more info | |||
3 |  British Patient Capital | 11 investment(s) investment(s) | 25 contacts contacts | |||
4 |  Cambridge Innovation Capital | 7 investment(s) investment(s) | 10 contacts contacts |
Click here for a full list of 6,908+ startup investors in the UK